ERBB2 and neoplasm: Newer systemic therapies for treating cerebral metastases may lead to significant differences in survival between different tumor types and comprehensive clinical data with large numbers would be needed to stratify cases in future, for example by HER2 responsiveness in breast carcinoma metastases.